Denmark In-Vitro Diagnostics Market Analysis -2030

Name: Denmark In-Vitro Diagnostics Market Analysis -2030
Creator: Next Move Strategy Consulting
Published: 2025-09-18T05:30:00+05:30

About Report

Download Now

Denmark In-Vitro Diagnostic Market by Product & Service (Reagents & Consumables, Instruments & Devices, Software & Services), by Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology & Coagulation, Microbiology, Urinalysis & Body Fluids, Other Techniques), by Testing Site / Channel (Central & Reference Laboratories, Hospital & Physician Labs, Point-of-Care & Retail, Home & Self-Testing), and Others – Opportunity Analysis and Industry Forecast, 2024–2030

Download PDF

Speak to Our Analyst

Denmark In-Vitro Diagnostics Market Overview

The Denmark In-Vitro Diagnostics Market size was valued at USD 555.00 million in 2023, and is predicted to reach USD 840.02 million by 2030, at a CAGR of 5.6% from 2024 to 2030. In-Vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Rising Burden of Chronic Diseases and Increasing Preventive Healthcare Focus

Denmark faces a steadily growing incidence of chronic diseases such as cancer, cardiovascular disorders, and diabetes, which are among the leading causes of mortality and long-term healthcare expenditure. According to national health data, cancer alone accounts for a major share of the disease burden, driving demand for early and accurate diagnostic solutions. Alongside this, Denmark’s strong emphasis on preventive healthcare has reinforced the role of IVD technologies in routine screening, risk stratification, and continuous monitoring, ensuring diagnostics remain integral to both treatment and prevention pathways.

Strong Government Support and Digital Health Integration Driving Market Expansio

The Danish government’s commitment to modernizing healthcare infrastructure is a central growth driver for the IVD market. Investments in laboratory automation, digital health platforms, and national e-health records are improving diagnostic efficiency and connectivity across hospitals, clinics, and community health centers. Denmark’s alignment with the European Union’s In Vitro Diagnostic Regulation (IVDR) further ensures adoption of high-quality diagnostic products. The integration of IVD systems with telehealth and digital platforms is expanding accessibility and strengthening real-time disease monitoring, making the sector a priority for healthcare innovation and funding.

High Cost of Advanced Diagnostics and Reimbursement Constraints

While Denmark maintains one of Europe’s most robust healthcare systems, the high cost associated with advanced molecular diagnostics and genetic testing remains a restraint. Budgetary pressures within the universal healthcare framework create reimbursement challenges for newer, more specialized assays, slowing their adoption in routine clinical practice. This financial barrier particularly impacts smaller diagnostic laboratories and community healthcare facilities, which may struggle to absorb the costs of advanced IVD systems, leading to uneven access across regions.

Growing Adoption of Point-of-care and Home-based Testing Solutions

The acceleration of point-of-care (POC) testing and home-based diagnostics represents a significant opportunity in Denmark’s IVD market. Driven by rising consumer demand for convenient and rapid testing, as well as the push to decentralize healthcare delivery, portable diagnostic devices are gaining ground in primary care centers, pharmacies, and home settings. Innovations in self-testing kits for infectious diseases, chronic condition monitoring, and personalized medicine are expanding the IVD footprint beyond hospitals, reducing healthcare system strain while improving patient empowerment and real-time health management.

Competitive Landscape

The promising players operating in the Denmark in-vitro diagnostics industry include F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott Laboratories A/S, Thermo Fisher Scientific Inc., Radiometer Medical ApS, Sysmex Corporation, Qiagen N.V., BioMérieux, Hologic, Bio-Rad Laboratories, SSI Diagnostica A/S, BioPorto Diagnostics A/S, Grifols S.A., Ortho Clinical Diagnostics, Agilent Technologies Denmark ApS, and others.

Denmark In-Vitro Diagnostic Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application / Disease Area

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

Key Players

F. Hoffmann-La Roche Ltd
Siemens Healthineers AG
Abbott Laboratories A/S
Thermo Fisher Scientific Inc.
Radiometer Medical ApS
Sysmex Corporation
Qiagen N.V.
BioMérieux
Hologic
Bio-Rad Laboratories
SSI Diagnostica A/S
BioPorto Diagnostics A/S
Grifols S.A.
Ortho Clinical Diagnostics
Agilent Technologies Denmark ApS

Report Scope and Segmentation

Parameters	Details
Market Size Value in 2023	USD 555.00 million
Revenue Forecast in 2030	USD 840.02 million
Value Growth Rate	CAGR of 5.6% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Million (USD)
Growth Factors	Rising Burden of Chronic Diseases and Increasing Preventive Healthcare Focus. Strong Government Support and Digital Health Integration Driving Market Expansio.
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

About the Author

Sikha Haritwal is a researcher with more than 5 years of experience. She has been keeping a close eye on several industry verticals, including construction & manufacturing, personal care products, and consumer electronics. She has avid interest in writing news articles and hopes to use blog as a platform to share her knowledge with others.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1. REPORT DESCRIPTION
2. 1.2. WHO SHOULD READ THIS REPORT
3. 1.3. KEY MARKET SEGMENTS
4. 1.4. RESEARCH METHODOLOGY
5. 1. 1.4.1 MARKET SIZE ESTIMATION METHODOLOGY
  2. 1. 1.4.1.1. TOP-DOWN AND BOTTOM-UP APPROACH
    2. 1.4.1.2. DEMAND AND SUPPLY-SIDE ANALYSIS
    3. 1.4.1.3. MACRO-INDICATOR APPROACH
  3. 1.4.2 DATA COLLECTION APPROACH
  4. 1. 1.4.2.1. PRIMARY DATA COLLECTION
    2. 1.4.2.2. SECONDARY DATA COLLECTION
  5. 1.4.3 SECONDARY DATA SOURCES
  6. 1.4.4 FORECASTING

1. 2.1. DEFINITION
2. 2.2. SCOPE

1. 3.1. MARKET SNAPSHOT, 2024 - 2030, MILLION USD

1. 4.1. MARKET DYNAMICS
2. 1. 4.1.1 DRIVERS
  2. 1. 4.1.1.1. RISING BURDEN OF CHRONIC DISEASES AND INCREASING PREVENTIVE HEALTHCARE FOCUS
    2. 4.1.1.2. STRONG GOVERNMENT SUPPORT AND DIGITAL HEALTH INTEGRATION DRIVING MARKET EXPANSION
  3. 4.1.2 RESTRAINTS
  4. 1. 4.1.2.1. HIGH COST OF ADVANCED DIAGNOSTICS AND REIMBURSEMENT CONSTRAINTS
  5. 4.1.3 OPPORTUNITIES
  6. 1. 4.1.3.1. GROWING ADOPTION OF POINT-OF-CARE AND HOME-BASED TESTING SOLUTIONS

1. 5.1. MARKET SHARE ANALYSIS OF TOP 10 DENMARK IN-VITRO DIAGNOSTICS PROVIDERS, 2024

1. 6.1 OVERVIEW
2. 6.2 REAGENTS AND CONSUMABLES MARKET
3. 1. 6.2.1 CLINICAL CHEMISTRY REAGENTS
  2. 6.2.2 IMMUNOASSAY REAGENTS (ELISA/CLIA)
  3. 6.2.3 MOLECULAR MASTER MIXES
  4. 6.2.4 HEMATOLOGY CONTROLS
4. 6.3 INSTRUMENTS AND DEVICES MARKET
5. 1. 6.3.1 CHEMISTRY ANALYZERS
  2. 6.3.2 IMMUNOASSAY SYSTEMS
  3. 6.3.3 MOLECULAR THERMOCYCLERS/SEQUENCERS
  4. 6.3.4 HEMATOLOGY ANALYZERS
  5. 6.3.5 POC DEVICES
6. 6.4 SOFTWARE AND SERVICES MARKET
7. 1. 6.4.1 LIS, DATA ANALYTICS
  2. 6.4.2 CRO/TESTING SERVICES

1. 7.1 OVERVIEW
2. 7.2 CLINICAL CHEMISTRY MARKET
3. 1. 7.2.1 METABOLITES
  2. 7.2.2 ELECTROLYTES
  3. 7.2.3 ENZYMES
4. 7.3 IMMUNOASSAYS MARKET
5. 1. 7.3.1 ELISA / CLIA / CMIA
  2. 7.3.2 LATERAL-FLOW RAPID TESTS
  3. 7.3.3 IMMUNOFLUORESCENCE
6. 7.4 MOLECULAR DIAGNOSTICS MARKET
7. 1. 7.4.1 PCR
  2. 7.4.2 ISOTHERMAL NAAT
  3. 7.4.3 NGS
  4. 7.4.4 IN-SITU HYBRIDIZATION
8. 7.5 HEMATOLOGY AND COAGULATION MARKET
9. 1. 7.5.1 CBC ANALYZERS
  2. 7.5.2 COAGULATION PANELS
10. 7.6 MICROBIOLOGY MARKET
11. 1. 7.6.1 CULTURE AND SENSITIVITY
  2. 7.6.2 MALDI-TOF
  3. 7.6.3 MOLECULAR ID
12. 7.7 URINALYSIS AND BODY FLUIDS MARKET
13. 7.8 OTHER TECHNIQUES MARKET

1. 8.1 OVERVIEW
2. 8.2 CENTRAL AND REFERENCE LABORATORIES MARKET
3. 8.3 HOSPITAL AND PHYSICIAN LABS MARKET
4. 8.4 POINT-OF-CARE AND RETAIL MARKET
5. 8.5 HOME AND SELF-TESTING MARKET

1. 9.1 OVERVIEW
2. 9.2 INFECTIOUS DISEASES MARKET
3. 9.3 ONCOLOGY MARKET
4. 9.4 CARDIOVASCULAR HEALTH MARKET
5. 9.5 ENDOCRINOLOGY AND DIABETES MARKET
6. 9.6 NEPHROLOGY MARKET
7. 9.7 GENETIC AND PRENATAL TESTING MARKET
8. 9.8 AUTOIMMUNE DISORDERS MARKET
9. 9.9 DRUG MONITORING AND TOXICOLOGY MARKET
10. 9.10 BLOOD SCREENING AND TYPING MARKET
11. 9.11 OTHER INDICATIONS MARKET

1. 10.1 F. HOFFMANN-LA ROCHE LTD
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 SIEMENS HEALTHINEERS AG
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 ABBOTT LABORATORIES A/S
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 THERMO FISHER SCIENTIFIC INC.
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 RADIOMETER MEDICAL APS
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 SYSMEX CORPORATION
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS
13. 10.7 QIAGEN N.V.
14. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
15. 10.8 BIOMÉRIEUX
16. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
17. 10.9 HOLOGIC
18. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
19. 10.10 BIO-RAD LABORATORIES
20. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS
21. 10.11 SSI DIAGNOSTICA A/S
22. 1. 10.11.1 COMPANY OVERVIEW
  2. 10.11.2 COMPANY SNAPSHOT
  3. 10.11.3 OPERATING BUSINESS SEGMENTS
  4. 10.11.4 PRODUCT PORTFOLIO
  5. 10.11.5 BUSINESS PERFORMANCE
  6. 10.11.6 BUSINESS SEGMENTS
  7. 10.11.7 GEOGRAPHIC SEGMENTS
  8. 10.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.11.9 PRIMARY MARKET COMPETITORS
23. 10.12 BIOPORTO DIAGNOSTICS A/S
24. 1. 10.12.1 COMPANY OVERVIEW
  2. 10.12.2 COMPANY SNAPSHOT
  3. 10.12.3 OPERATING BUSINESS SEGMENTS
  4. 10.12.4 PRODUCT PORTFOLIO
  5. 10.12.5 BUSINESS PERFORMANCE
  6. 10.12.6 BUSINESS SEGMENTS
  7. 10.12.7 GEOGRAPHIC SEGMENTS
  8. 10.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.12.9 PRIMARY MARKET COMPETITORS
25. 10.13 GRIFOLS S.A.
26. 1. 10.13.1 COMPANY OVERVIEW
  2. 10.13.2 COMPANY SNAPSHOT
  3. 10.13.3 OPERATING BUSINESS SEGMENTS
  4. 10.13.4 PRODUCT PORTFOLIO
  5. 10.13.5 BUSINESS PERFORMANCE
  6. 10.13.6 BUSINESS SEGMENTS
  7. 10.13.7 GEOGRAPHIC SEGMENTS
  8. 10.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.13.9 PRIMARY MARKET COMPETITORS
27. 10.14 ORTHO CLINICAL DIAGNOSTICS
28. 1. 10.14.1 COMPANY OVERVIEW
  2. 10.14.2 COMPANY SNAPSHOT
  3. 10.14.3 OPERATING BUSINESS SEGMENTS
  4. 10.14.4 PRODUCT PORTFOLIO
  5. 10.14.5 BUSINESS PERFORMANCE
  6. 10.14.6 BUSINESS SEGMENTS
  7. 10.14.7 GEOGRAPHIC SEGMENTS
  8. 10.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.14.9 PRIMARY MARKET COMPETITORS
29. 10.15 AGILENT TECHNOLOGIES DENMARK APS
30. 1. 10.15.1 COMPANY OVERVIEW
  2. 10.15.2 COMPANY SNAPSHOT
  3. 10.15.3 OPERATING BUSINESS SEGMENTS
  4. 10.15.4 PRODUCT PORTFOLIO
  5. 10.15.5 BUSINESS PERFORMANCE
  6. 10.15.6 BUSINESS SEGMENTS
  7. 10.15.7 GEOGRAPHIC SEGMENTS
  8. 10.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. DENMARK IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT AND SERVICE, 2024-2030, (MILLION USD)
TABLE 2. REAGENTS AND CONSUMABLES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 3. CLINICAL CHEMISTRY REAGENTS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 4. IMMUNOASSAY REAGENTS (ELISA/CLIA), MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 5. MOLECULAR MASTER MIXES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 6. HEMATOLOGY CONTROLS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 7. INSTRUMENTS AND DEVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 8. CHEMISTRY ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 9. IMMUNOASSAY SYSTEMS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 10. MOLECULAR THERMOCYCLERS/SEQUENCERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 11. HEMATOLOGY ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 12. POC DEVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 13. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 14. LIS, DATA ANALYTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 15. CRO/TESTING SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 16. DENMARK IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (MILLION USD)
TABLE 17. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 18. METABOLITES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 19. ELECTROLYTES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 20. ENZYMES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 21. IMMUNOASSAYS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 22. ELISA / CLIA / CMIA, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 23. LATERAL-FLOW RAPID TESTS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 24. IMMUNOFLUORESCENCE, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 25. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 26. PCR, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 27. ISOTHERMAL NAAT, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 28. NGS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 29. IN-SITU HYBRIDIZATION, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 30. HEMATOLOGY AND COAGULATION, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 31. CBC ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 32. COAGULATION PANELS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 33. MICROBIOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 34. CULTURE AND SENSITIVITY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 35. MALDI-TOF, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 36. MOLECULAR ID, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 37. URINALYSIS AND BODY FLUIDS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 38. OTHER TECHNIQUES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 39. DENMARK IN-VITRO DIAGNOSTICS MARKET VALUE, BY TESTING SITE / CHANNEL, 2024-2030, (MILLION USD)
TABLE 40. CENTRAL AND REFERENCE LABORATORIES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 41. HOSPITAL AND PHYSICIAN LABS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 42. POINT-OF-CARE AND RETAIL, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 43. HOME AND SELF-TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 44. DENMARK IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION / DISEASE AREA, 2024-2030, (MILLION USD)
TABLE 45. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 46. ONCOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 47. CARDIOVASCULAR HEALTH, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 48. ENDOCRINOLOGY AND DIABETES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 49. NEPHROLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 50. GENETIC AND PRENATAL TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 51. AUTOIMMUNE DISORDERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 52. DRUG MONITORING AND TOXICOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 53. BLOOD SCREENING AND TYPING, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 54. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 55. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 56. F. HOFFMANN-LA ROCHE LTD: OPERATING BUSINESS SEGMENTS
TABLE 57. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 58. F. HOFFMANN-LA ROCHE LTD: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 59. F. HOFFMANN-LA ROCHE LTD: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 60. F. HOFFMANN-LA ROCHE LTD: KEY STRATERGY
TABLE 61. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 62. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 63. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 64. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 65. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 66. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 67. ABBOTT LABORATORIES A/S: COMPANY SNAPSHOT
TABLE 68. ABBOTT LABORATORIES A/S: OPERATING BUSINESS SEGMENTS
TABLE 69. ABBOTT LABORATORIES A/S: PRODUCT PORTFOLIO
TABLE 70. ABBOTT LABORATORIES A/S: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 71. ABBOTT LABORATORIES A/S: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 72. ABBOTT LABORATORIES A/S: KEY STRATERGY
TABLE 73. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
TABLE 74. THERMO FISHER SCIENTIFIC INC.: OPERATING BUSINESS SEGMENTS
TABLE 75. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 76. THERMO FISHER SCIENTIFIC INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 77. THERMO FISHER SCIENTIFIC INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 78. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGY
TABLE 79. RADIOMETER MEDICAL APS: COMPANY SNAPSHOT
TABLE 80. RADIOMETER MEDICAL APS: OPERATING BUSINESS SEGMENTS
TABLE 81. RADIOMETER MEDICAL APS: PRODUCT PORTFOLIO
TABLE 82. RADIOMETER MEDICAL APS: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 83. RADIOMETER MEDICAL APS: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 84. RADIOMETER MEDICAL APS: KEY STRATERGY
TABLE 85. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 86. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 87. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 88. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 89. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 90. SYSMEX CORPORATION: KEY STRATERGY
TABLE 91. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 92. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 93. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 94. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 95. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 96. QIAGEN N.V.: KEY STRATERGY
TABLE 97. BIOMÉRIEUX: COMPANY SNAPSHOT
TABLE 98. BIOMÉRIEUX: OPERATING BUSINESS SEGMENTS
TABLE 99. BIOMÉRIEUX: PRODUCT PORTFOLIO
TABLE 100. BIOMÉRIEUX: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 101. BIOMÉRIEUX: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 102. BIOMÉRIEUX: KEY STRATERGY
TABLE 103. HOLOGIC: COMPANY SNAPSHOT
TABLE 104. HOLOGIC: OPERATING BUSINESS SEGMENTS
TABLE 105. HOLOGIC: PRODUCT PORTFOLIO
TABLE 106. HOLOGIC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 107. HOLOGIC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 108. HOLOGIC: KEY STRATERGY
TABLE 109. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
TABLE 110. BIO-RAD LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 111. BIO-RAD LABORATORIES: PRODUCT PORTFOLIO
TABLE 112. BIO-RAD LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 113. BIO-RAD LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 114. BIO-RAD LABORATORIES: KEY STRATERGY
TABLE 115. SSI DIAGNOSTICA A/S: COMPANY SNAPSHOT
TABLE 116. SSI DIAGNOSTICA A/S: OPERATING BUSINESS SEGMENTS
TABLE 117. SSI DIAGNOSTICA A/S: PRODUCT PORTFOLIO
TABLE 118. SSI DIAGNOSTICA A/S: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 119. SSI DIAGNOSTICA A/S: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 120. SSI DIAGNOSTICA A/S: KEY STRATERGY
TABLE 121. BIOPORTO DIAGNOSTICS A/S: COMPANY SNAPSHOT
TABLE 122. BIOPORTO DIAGNOSTICS A/S: OPERATING BUSINESS SEGMENTS
TABLE 123. BIOPORTO DIAGNOSTICS A/S: PRODUCT PORTFOLIO
TABLE 124. BIOPORTO DIAGNOSTICS A/S: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 125. BIOPORTO DIAGNOSTICS A/S: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 126. BIOPORTO DIAGNOSTICS A/S: KEY STRATERGY
TABLE 127. GRIFOLS S.A.: COMPANY SNAPSHOT
TABLE 128. GRIFOLS S.A.: OPERATING BUSINESS SEGMENTS
TABLE 129. GRIFOLS S.A.: PRODUCT PORTFOLIO
TABLE 130. GRIFOLS S.A.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 131. GRIFOLS S.A.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 132. GRIFOLS S.A.: KEY STRATERGY
TABLE 133. ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 134. ORTHO CLINICAL DIAGNOSTICS: OPERATING BUSINESS SEGMENTS
TABLE 135. ORTHO CLINICAL DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 136. ORTHO CLINICAL DIAGNOSTICS: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 137. ORTHO CLINICAL DIAGNOSTICS: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 138. ORTHO CLINICAL DIAGNOSTICS: KEY STRATERGY
TABLE 139. AGILENT TECHNOLOGIES DENMARK APS: COMPANY SNAPSHOT
TABLE 140. AGILENT TECHNOLOGIES DENMARK APS: OPERATING BUSINESS SEGMENTS
TABLE 141. AGILENT TECHNOLOGIES DENMARK APS: PRODUCT PORTFOLIO
TABLE 142. AGILENT TECHNOLOGIES DENMARK APS: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 143. AGILENT TECHNOLOGIES DENMARK APS: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 144. AGILENT TECHNOLOGIES DENMARK APS: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. DENMARK IN-VITRO DIAGNOSTICS MARKET VALUE, BY PRODUCT AND SERVICE, 2024-2030, (MILLION USD)
FIGURE 7. REAGENTS AND CONSUMABLES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 8. CLINICAL CHEMISTRY REAGENTS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 9. IMMUNOASSAY REAGENTS (ELISA/CLIA), MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 10. MOLECULAR MASTER MIXES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 11. HEMATOLOGY CONTROLS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 12. INSTRUMENTS AND DEVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 13. CHEMISTRY ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 14. IMMUNOASSAY SYSTEMS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 15. MOLECULAR THERMOCYCLERS/SEQUENCERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 16. HEMATOLOGY ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 17. POC DEVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 18. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 19. LIS, DATA ANALYTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 20. CRO/TESTING SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 21. DENMARK IN-VITRO DIAGNOSTICS MARKET VALUE, BY TECHNIQUE, 2024-2030, (MILLION USD)
FIGURE 22. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 23. METABOLITES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 24. ELECTROLYTES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 25. ENZYMES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 26. IMMUNOASSAYS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 27. ELISA / CLIA / CMIA, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 28. LATERAL-FLOW RAPID TESTS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 29. IMMUNOFLUORESCENCE, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 30. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 31. PCR, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 32. ISOTHERMAL NAAT, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 33. NGS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 34. IN-SITU HYBRIDIZATION, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 35. HEMATOLOGY AND COAGULATION, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 36. CBC ANALYZERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 37. COAGULATION PANELS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 38. MICROBIOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 39. CULTURE AND SENSITIVITY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 40. MALDI-TOF, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 41. MOLECULAR ID, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 42. URINALYSIS AND BODY FLUIDS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 43. OTHER TECHNIQUES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 44. DENMARK IN-VITRO DIAGNOSTICS MARKET VALUE, BY TESTING SITE / CHANNEL, 2024-2030, (MILLION USD)
FIGURE 45. CENTRAL AND REFERENCE LABORATORIES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 46. HOSPITAL AND PHYSICIAN LABS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 47. POINT-OF-CARE AND RETAIL, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 48. HOME AND SELF-TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 49. DENMARK IN-VITRO DIAGNOSTICS MARKET VALUE, BY APPLICATION / DISEASE AREA, 2024-2030, (MILLION USD)
FIGURE 50. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 51. ONCOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 52. CARDIOVASCULAR HEALTH, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 53. ENDOCRINOLOGY AND DIABETES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 54. NEPHROLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 55. GENETIC AND PRENATAL TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 56. AUTOIMMUNE DISORDERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 57. DRUG MONITORING AND TOXICOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 58. BLOOD SCREENING AND TYPING, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 59. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 60. F. HOFFMANN-LA ROCHE LTD: NET SALES, (2022-2024)
FIGURE 61. F. HOFFMANN-LA ROCHE LTD: PRIMARY MARKET COMPETITORS
FIGURE 62. SIEMENS HEALTHINEERS AG: NET SALES, (2022-2024)
FIGURE 63. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 64. ABBOTT LABORATORIES A/S: NET SALES, (2022-2024)
FIGURE 65. ABBOTT LABORATORIES A/S: PRIMARY MARKET COMPETITORS
FIGURE 66. THERMO FISHER SCIENTIFIC INC.: NET SALES, (2022-2024)
FIGURE 67. THERMO FISHER SCIENTIFIC INC.: PRIMARY MARKET COMPETITORS
FIGURE 68. RADIOMETER MEDICAL APS: NET SALES, (2022-2024)
FIGURE 69. RADIOMETER MEDICAL APS: PRIMARY MARKET COMPETITORS
FIGURE 70. SYSMEX CORPORATION: NET SALES, (2022-2024)
FIGURE 71. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 72. QIAGEN N.V.: NET SALES, (2022-2024)
FIGURE 73. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 74. BIOMÉRIEUX: NET SALES, (2022-2024)
FIGURE 75. BIOMÉRIEUX: PRIMARY MARKET COMPETITORS
FIGURE 76. HOLOGIC: NET SALES, (2022-2024)
FIGURE 77. HOLOGIC: PRIMARY MARKET COMPETITORS
FIGURE 78. BIO-RAD LABORATORIES: NET SALES, (2022-2024)
FIGURE 79. BIO-RAD LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 80. SSI DIAGNOSTICA A/S: NET SALES, (2022-2024)
FIGURE 81. SSI DIAGNOSTICA A/S: PRIMARY MARKET COMPETITORS
FIGURE 82. BIOPORTO DIAGNOSTICS A/S: NET SALES, (2022-2024)
FIGURE 83. BIOPORTO DIAGNOSTICS A/S: PRIMARY MARKET COMPETITORS
FIGURE 84. GRIFOLS S.A.: NET SALES, (2022-2024)
FIGURE 85. GRIFOLS S.A.: PRIMARY MARKET COMPETITORS
FIGURE 86. ORTHO CLINICAL DIAGNOSTICS: NET SALES, (2022-2024)
FIGURE 87. ORTHO CLINICAL DIAGNOSTICS: PRIMARY MARKET COMPETITORS
FIGURE 88. AGILENT TECHNOLOGIES DENMARK APS: NET SALES, (2022-2024)
FIGURE 89. AGILENT TECHNOLOGIES DENMARK APS: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The Denmark in-vitro diagnostics market is estimated to reach USD 840.02 million by 2030.

The key players in the Denmark in-vitro diagnostics market include F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Abbott Laboratories A/S, Thermo Fisher Scientific Inc., Radiometer Medical ApS, Sysmex Corporation, Qiagen N.V., BioMérieux, Hologic, Bio-Rad Laboratories, SSI Diagnostica A/S, BioPorto Diagnostics A/S, Grifols S.A., Ortho Clinical Diagnostics, Agilent Technologies Denmark ApS and others.

The Denmark in-vitro diagnostics market was estimate to reach USD 555.00 million in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the market growth.

Introduction of Point-of-Care Testing Solutions creates opportunities for the in-vitro diagnostics in the coming future.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Multi User

$2,575

Single User

$1,575

Enterprise

$3,875

Datapack

$1,975

Download Sample

Inquire Before Buying

Speak to Our Analyst

Share with Peers

Request Sample